$TSM just crushed Q2 earnings Net Income: NT$706.56B (+23.4% YoY vs NT$632.6B expected) Gross Margin: Massive 67.7% (beating top-end guidance) Revenue: NT$1.27T (+36% YoY)AI hardware demand remains unstoppable. Full details: TSMC Investor Relations #TSMC #AI #Stocks $TSM

Tomorrow is D-Day for $TSMC. Revenue is already at record highs, but the real test happens tomorrow. Will guidance and AI demand justify the recent stock pullback or are we heading lower? #TSMC #AI #Stocks $TSM

Massive comeback for Q32 Bio $QTTB! Shares skyrocketed over 80% today after crushing expectations with positive Phase 2a data for its alopecia (hair loss) drug, bempikibart. Oppenheimer immediately doubled its price target to $40.

Oracle $ORCL is crashing despite good earnings. The market is terrified of massive AI debt and the huge dependence on OpenAI. Is this a debt trap or the ultimate buy-the-dip opportunity?

Even blowout earnings from Samsung couldn’t satisfy the market’s sky-high expectations. A massive global tech & chip selloff is wiping out gains today. AI hardware plays are officially priced for perfection. Are you buying the dip? $SOXX $MU $NVDA $ASML

B. Riley initiates $NUAI with a BUY and a massive $10 Price Target! With shares at $4.76, that's 100%+ upside potential Analysts see big value in New Era Energy & Digital for the AI infrastructure boom. #AI #StocksToWatch #Trading

$OCGN is entering a massive Q3 2026! Rolling BLA submission for OCU400 kicks off this quarter. Plus, upcoming July catalysts: • July 10: Piper Sandler Fireside Chat • July 17: 1-year ArMaDa study data Full schedule & details here: BioSpace Press Release #Ocugen #Biotech

Regulatory update for $LPK: DWS Investment GmbH has slightly adjusted its position and now holds a 2.92% stake, just below the 3% disclosure threshold. Keeping an eye on the institutional movement ahead of the H1 report. #stocks #trading #LPKF

$NUAI: With the new leadership team at the helm, the shift into AI data center infrastructure is accelerating. Exciting phase ahead, very curious to watch how this next chapter unfolds! #AI #Infrastructure #NUAI #Leadership

Market drop on $Meta news dragged $LPK down. With the H1 report coming up at the end of July, I just bought some shares last night. Curious to see how this plays out. #stocks #trading #LPKF

$VKTX Markets are reacting to Viking Therapeutics expanding beyond its lead asset VK2735. The newly initiated Phase 1 study for VK3019 targets amylin & calcitonin receptors to tackle obesity from a new angle. Full Report: boerse-express.com/news/arti… #Biotech #Stocks

$OCGN Update FDA BLA Starts July 1: #Ocugen begins rolling FDA submission tomorrow for OCU400 gene therapy. Funded Until 2028: May's $130M raise fully secures all clinical operations.

Half-Year Finale: Post-Russell Watch Yesterday: Huge jumps in $NUAI, $DARE & $OUST via ETF buying. Today: Q2 closes. Institutional "window dressing" dominates. Don't chase the green. Wait for the dust to settle. Eyes on the Q3 catalyst rush! #Investing

Russell Index Inclusions $NUAI: Jumps +10% to ~$6.47 on official Russell 3000 & Microcap Index entry. High ETF buying volume. $DARE: Gains +4.5% to ~$2.09 joining the Russell 3000E Index amid Flora Sync LF5 commercial revenue launch. #NUAI #DARE #Russell3000 #StocksToWatch

$LPKF Laser & Electronics $LPK News Major Stake: British hedge fund Marshall Wace (MW Group) officially crossed the 3% threshold. New Position: The fund now controls a 3.14% voting rights stake in LPKF as of today's regulatory filing. finanzen.at/nachrichten/akti…

$LRMR submits first module of Rolling BLA to FDA for accelerated approval of Nomlabofusp. Long-term Phase 2 data shows sustained increases in frataxin levels and stable safety profile for up to 2 years. Target commercial launch set for mid-2027.